Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Genmab announced updated Phase 2 trial results for petosemtamab, a bispecific antibody targeting EGFR and LGR5, showing encouraging objective response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer patients when combined with standard chemotherapy. The data demonstrates durable responses and supports the ongoing global Phase 3 development program.